|
?:abstract
|
-
PURPOSE: To summarize the clinical features and effective therapy of severe COVID-19 patients PATIENTS AND METHODS: In this retrospective, multicenter study, the medical records of COVID-19 patients in Hunan, from January 21, 2020 to February 19, 2020 were reviewed RESULTS: Of the 350 COVID-19 patients, 13 7% were severe cases On admission, compared with non-severe patients, more severe patients had a neutrophil/lymphocyte ratio > 3 (58 3% vs 33 8%, P=0 001), D-dimer > 1 mg/L (41 7% vs 13 6%, P<0 0001), higher level of CRP (39 1 mg/L, IQR18 1-75 9 vs 13 4 mg/L, IQR5 0-32 8, P<0 0001), and multiple pneumonia on CT (77 1% vs 18 2%, P<0 0001) All severe patients received oxygen support 95 8% of them received antivirals, and the most frequent therapy was lopinavir and ritonavir plus human interferon-α2b Moxifloxacin was used in 70 8% severe patients The total dosage of methylprednisolone sodium succinate was 640 mg (IQR 360-960) in severe patients, and the duration of use was 8 5 days (IQR 6 8-11 3) The total dosage of immunoglobulin was 80 g (IQR, 60-140) in severe patients, and the duration was 8 0 days (IQR, 6 0-11 5) As of March 15, 2020, 95 8% of the severe patients had been discharged and only two deaths occurred CONCLUSION: The rate of severe cases and mortality of COVID-19 in Hunan are lower than those in Wuhan In addition to antivirals and oxygen support, timely interventions including corticosteroids, immunoglobulin, and antibiotics, contribute to improving the prognosis of severe COVID-19 patients
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}